BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 38729313)

  • 21. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic insulinoma: A single-center experience.
    Borrelli de Andreis F; Boškoski I; Mascagni P; Schepis T; Bianchi A; Schinzari G; Annicchiarico BE; Quero G; Tortora G; Alfieri S; Gasbarrini A; Costamagna G; Spada C; Attili F
    Pancreatology; 2023 Aug; 23(5):543-549. PubMed ID: 37236853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study.
    Chanez B; Caillol F; Ratone JP; Pesenti C; Rochigneux P; Pignot G; Thomassin J; Brunelle S; Walz J; Salem N; Giovannini M; Gravis G
    Cancers (Basel); 2021 Oct; 13(21):. PubMed ID: 34771431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study.
    Oh D; Seo DW; Song TJ; Park DH; Lee SK; Kim MH
    Endosc Ultrasound; 2022; 11(1):68-74. PubMed ID: 35083978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial experience of EUS-guided radiofrequency ablation of unresectable pancreatic cancer.
    Song TJ; Seo DW; Lakhtakia S; Reddy N; Oh DW; Park DH; Lee SS; Lee SK; Kim MH
    Gastrointest Endosc; 2016 Feb; 83(2):440-3. PubMed ID: 26344883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA) of the Pancreas in a Porcine Model.
    Gaidhane M; Smith I; Ellen K; Gatesman J; Habib N; Foley P; Moskaluk C; Kahaleh M
    Gastroenterol Res Pract; 2012; 2012():431451. PubMed ID: 23049547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors.
    Pai M; Habib N; Senturk H; Lakhtakia S; Reddy N; Cicinnati VR; Kaba I; Beckebaum S; Drymousis P; Kahaleh M; Brugge W
    World J Gastrointest Surg; 2015 Apr; 7(4):52-9. PubMed ID: 25914783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
    Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
    Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EUS-guided Radiofrequency Ablation (EUS-RFA) of Solid Pancreatic Neoplasm Using an 18-gauge Needle Electrode: Feasibility, Safety, and Technical Success.
    Crinò SF; D'Onofrio M; Bernardoni L; Frulloni L; Iannelli M; Malleo G; Paiella S; Larghi A; Gabbrielli A
    J Gastrointestin Liver Dis; 2018 Mar; 27(1):67-72. PubMed ID: 29557417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neoadjuvant Chemotherapy Followed by Radiofrequency Ablation Prolongs Survival for Ablatable Colorectal Liver Metastasis: A Propensity Score Matching Comparative Study.
    Chen Y; Xu Y; Xu L; Han F; Huang Y; Jiang H; Wu J; Zhang Y
    Front Oncol; 2021; 11():758552. PubMed ID: 34745996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
    Motoi F; Ishida K; Fujishima F; Ottomo S; Oikawa M; Okada T; Shimamura H; Takemura S; Ono F; Akada M; Nakagawa K; Katayose Y; Egawa S; Unno M
    Ann Surg Oncol; 2013 Nov; 20(12):3794-801. PubMed ID: 23838925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neuroendocrine Tumors: A Systematic Review and Metanalysis.
    Armellini E; Facciorusso A; Crinò SF
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837560
    [No Abstract]   [Full Text] [Related]  

  • 34. P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with neoadjuvant therapy.
    Oshima M; Okano K; Kamada H; Suto H; Ando Y; Ibuki E; Ishikawa R; Masaki T; Haba R; Suzuki Y
    J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):802-814. PubMed ID: 36448271
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasound for the Guidance and Monitoring of Endoscopic Radiofrequency Ablation.
    Choi JH; Seo DW; Song TJ; Park DH; Lee SS; Lee SK; Kim MH
    Gut Liver; 2020 Nov; 14(6):826-832. PubMed ID: 32000466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endoscopic ultrasound-guided perivascular pancreatic radiofrequency ablation using a hydroxyethyl starch solution prior to pancreatectomy.
    Montanelli J; Sosa-Valencia L; Badaoui A; Averous G; Swanstrom L; Mutter D; Pessaux P; Seeliger B
    Endosc Int Open; 2023 Dec; 11(12):E1123-E1129. PubMed ID: 38094033
    [No Abstract]   [Full Text] [Related]  

  • 39. Current role of endoscopic ultrasound in the diagnosis and management of pancreatic cancer.
    Salom F; Prat F
    World J Gastrointest Endosc; 2022 Jan; 14(1):35-48. PubMed ID: 35116098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future.
    Pandya GJ; Shelat VG
    World J Gastrointest Oncol; 2015 Feb; 7(2):6-11. PubMed ID: 25685272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.